Evaluating Patients With Impaired Hepatic Function

This study has been completed.
Sponsor:
Information provided by:
Taiho Pharma USA, Inc.
ClinicalTrials.gov Identifier:
NCT00398424
First received: November 8, 2006
Last updated: August 6, 2009
Last verified: August 2009
  Purpose

This is a Phase I, Open-Label study evaluating the PK of S-1 components and their metabolites in patients with advanced solid tumors and varying degrees of hepatic function defined by the NCI classification for hepatic impairment. Patients will be stratified into 4 Cohorts- Normal, Mild, Moderate or Severe.

Six patients will be enrolled inot each cohort and receive S-1.


Condition Intervention Phase
Impaired Hepatic Function
Drug: S-1/Cisplatin
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I, Open-Label Study Evaluating The Pharmacokinetics of Components of S-1 Patients With Impaired Hepatic Function

Resource links provided by NLM:


Further study details as provided by Taiho Pharma USA, Inc.:

Primary Outcome Measures:
  • To provide specific dosing recommendations for S-1 in patients with hepatic impairment based on the PK of S-1 and its components after single dose and during steady state condition [ Time Frame: The Pharmacokinetic Phase (Part 1) of the study will last 24 days. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To assess the antitumor activity and safety profile of S-1 in patients with impaired hepatic function [ Time Frame: Each cycle of the Extension Phase (Part 2) will be 21 days (14 days of S-1 treatment, 7 days recovery). The end of study for the Extension Phase will be 30 days after the last dose of S-1. ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 24
Study Start Date: February 2006
Study Completion Date: March 2009
Primary Completion Date: November 2008 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: S-1/Cisplatin

    PK Phase (Part 1), Beginning on Day 1 of the Pharmacokinetic Phase, 30 mg/m2 S-1 will be administered orally BID for 14 days (Days 1 through 14), followed by a 1-week recovery period.

    On Day -2 and Day 14 of the Pharmacokinetic Phase, all patients will receive a single dose of 30 mg/m2 S-1 administered orally.

    Extension Phase, Patients will receive S-1 at the dose that they tolerated in the PK Phase. S-1 will be administered orally BID for 2 weeks (Day 1 through Day 14) followed by a 1-week recovery period (Day 15 through Day 21). This cycle will be repeated every 3 weeks.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

A patient must meet all of the following inclusion criteria to be eligible for enrollment in this study:

  1. Has histologically or cytologically proven advanced solid tumors for which no standard therapy exists.
  2. Has provided written informed consent.
  3. Is 18 years of age or older.
  4. Is able to take medications orally.
  5. Has Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to ≤ 2 (Appendix A, ECOG Performance Status).
  6. Has adequate organ function as defined by the following criteria:

    1. Absolute granulocyte count ≥ 1,500/mm3 (ie, ≥ 1.5 x 109/L by International Units [IU]).
    2. Has a platelet count ≥ 100,000/mm3 (IU: ≥ 100 x 109/L).
    3. Has a hemoglobin value of ≥ 9.0 g/dL.
    4. Has a calculated creatinine clearance > 60 mL/min (by Cockcroft-Gault
  7. Is willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion Criteria

Exclude a patient from this study if he/she does not fulfill the inclusion criteria, or if any of the following conditions are observed:

  1. Has had treatment with any of the following within the specified time frame prior to study drug administration:

    1. Any investigational agent received either concurrently or within the last 30 days.
    2. Previous therapy for malignancy within 21 days, including any chemotherapy, immunotherapy, biologic or hormonal therapy (6 weeks for nitrosoureas or mitomycin C).
    3. Previous radiotherapy within 14 days.
    4. Current enrollment in another clinical trial.
    5. Required shunting or stenting of the liver within prior 28 days or planned during the first study treatment cycle.
  2. Has a serious illness or medical condition(s) including, but not limited to, the following:

    1. Myocardial infarction within the last 6 months, severe/unstable angina, congestive heart failure (New York Heart Association [NYHA] Class III or IV, see Appendix F, NYHA Classification).
    2. Known (at the time of entry) gastrointestinal disorder, including malabsorption,chronic nausea, vomiting, or diarrhea present to the extent that it might interfere with oral intake and absorption of the study medication.
    3. Previous organ allograft, including liver transplantation.
    4. Known brain metastasis.
    5. Known leptomeningeal metastases.
    6. Manifest ascites.
    7. Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness.
    8. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the Investigator would make the patient inappropriate for entry into this study. • 3. Is receiving a concomitant treatment with drugs interacting with S-1. The following drugs are prohibited because there may be an interaction with S-1:
    1. Sorivudine, uracil, dipyridamole, cimetidine and folinic acid (may enhance S-1 activity).
    2. Allopurinol (may diminish S-1 activity).
    3. Phenytoin (S-1 may enhance phenytoin activity).
    4. Flucytosine, a fluorinated pyrimidine antifungal agent (may enhance S-1 and flucytosine activity).
    5. Pilocarpine (may inhibit CYP2A6 activity).

4. Has known sensitivity to 5-FU. 5. Is a pregnant or lactating female. 6. Is a patient with reproductive potential who refuses to use an adequate means of contraception (including male patients).

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00398424

Locations
United States, Arizona
Premiere Oncology of Arizona
Scottsdale, Arizona, United States, 85260
United States, Connecticut
Yale Cancer Center
New Haven, Connecticut, United States, 06520
United States, Kentucky
University of Kentucky/Division of Hematology/Oncology and Blood Marrow Transplantation
Lexington, Kentucky, United States, 40536
United States, Maryland
University of Maryland/Greenebaum Cancer Center
Baltimore, Maryland, United States, 21201
United States, Missouri
Washington University School of Medicine
St Louis, Missouri, United States, 63110
United States, Texas
The Institute for Drug Development
San Antonio, Texas, United States, 78245
Sponsors and Collaborators
Taiho Pharma USA, Inc.
  More Information

No publications provided

Responsible Party: Peter Urrea/Senior VP Clinical and Regulatory Affairs, Taiho Pharma USA, Inc.
ClinicalTrials.gov Identifier: NCT00398424     History of Changes
Other Study ID Numbers: TPU-S1112
Study First Received: November 8, 2006
Last Updated: August 6, 2009
Health Authority: United States: Food and Drug Administration

Keywords provided by Taiho Pharma USA, Inc.:
Impaired Hepatic Function

Additional relevant MeSH terms:
Cisplatin
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Radiation-Sensitizing Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on April 17, 2014